论文部分内容阅读
目的探讨肿瘤患者血清中肿瘤标志物癌胚抗原(CEA)、癌相关糖抗原125和199水平的变化及其在肿瘤辅助诊断中的应用价值。方法采用化学发光微粒免疫分析法检测60例结直肠癌患者、25例肺癌患者、40例胃癌患者、15例食管癌患者、18例膀胱癌患者、16例宫颈癌患者和50例健康人血清中CEA、CA12-5和CA19-9的水平。结果结直肠癌、肺癌和胃癌患者的CEA、CA12-5和CA19-9水平及阳性率均明显高于对照组,差异有统计学意义(P<0.01);宫颈癌患者CA125水平及阳性率均明显高于对照组,差异有统计学意义(P<0.01)。结论 CEA、CA12-5和CA19-9对于肿瘤的辅助诊断有一定的临床参考价值,联合检测的阳性率更高,膀胱癌、食管癌和宫颈癌患者更应结合临床症状、手术及病理检查。
Objective To investigate the changes of carcinoembryonic antigen (CEA), the levels of cancer related carbohydrate antigens125 and 199 in serum of patients with cancer and its value in the diagnosis of tumor. Methods Chemiluminescent microparticle immunoassay was used to detect 60 patients with colorectal cancer, 25 patients with lung cancer, 40 patients with gastric cancer, 15 patients with esophageal cancer, 18 patients with bladder cancer, 16 patients with cervical cancer and 50 healthy people CEA, CA12-5 and CA19-9 levels. Results The positive rates of CEA, CA12-5 and CA19-9 in patients with colorectal cancer, lung cancer and gastric cancer were significantly higher than those in the control group (P <0.01). The levels of CA125 and the positive rate in patients with cervical cancer The difference was statistically significant (P <0.01). Conclusions CEA, CA12-5 and CA19-9 have certain clinical value for the diagnosis of tumors. The positive rate of combined detection is higher. Patients with bladder cancer, esophageal cancer and cervical cancer should be combined with clinical symptoms, surgery and pathological examination.